NDA 209500 · Intra-Cellular
Caplyta
Lumateperone Tosylate · Oral · Atypical Antipsychotic
NovelLast checked: Nov 20, 2026Latest source record: Apr 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 20, 2019
Approved uses
5
Original approval plus efficacy supplements
Registered trials
39
21 Phase 3, 11 recruiting
FAERS reports
7,706
2,180 serious, 65 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.2) ]. The safety and effectiveness of CAPLYTA have not been established in pediatric patients [see Use in Specific Populations (8.4) ]. WARNING:...
What it is approved for
From the label in effect Nov 5, 2026.
CAPLYTA is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ] . Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate [see Clinical Studies (14.2) ] . Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.3 ) ]. CAPLYTA is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 ) Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. ( 1 ) Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. ( 1 )
Mechanism: The mechanism of action of lumateperone for the treatment of schizophrenia in adults, for the treatment of depressive episodes associated with bipolar depression (as monotherapy or as adjunctive therapy with lithium or valproate), and as adjunctive therapy with antidepressants for the treatment of MDD is unknown. However, the mechanism of action of lumateperone for these uses could be mediated through a combination of antagonist activity at central serotonin 5-HT 2A receptors, and partial agonist activity at central dopamine D 2 receptors.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 24, 2026 Supplement 17 · Efficacy LetterLabel
- Nov 5, 2025 Supplement 16 · Efficacy LetterLabelMedication Guide
- Dec 17, 2021 Supplement 6 · Efficacy LabelLetterReview
- Dec 17, 2021 Supplement 5 · Efficacy LabelLetterReview
- Dec 20, 2019 Original approval · Type 1 - New Molecular Entity NovelReviewLetter
3 products under this application
- CAPLYTA · LUMATEPERONE TOSYLATE EQ 21MG BASE · CAPSULE, ORAL · Prescription
- CAPLYTA · LUMATEPERONE TOSYLATE EQ 42MG BASE · CAPSULE, ORAL · Prescription
- CAPLYTA · LUMATEPERONE TOSYLATE EQ 10.5MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lumateperone" as an intervention, any sponsor and status, largest first.
- An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT05061719 · 812 participants · Start Oct 8, 2021 · Primary completion Oct 14, 2024
Drug: Lumateperone · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Bentonville, Arkansas; Little Rock, Arkansas · 109 sites in all
- A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of TreatmentPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT02469155 · 696 participants · Start Jun 2015 · Primary completion Aug 2016
Drug: ITI-007; Risperidone and 1 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Springdale, Arkansas; Culver City, California · 11 sites in all
- Lumateperone for the Prevention of Relapse in Patients With SchizophreniaPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT04959032 · 592 participants · Start Jul 8, 2021 · Primary completion Jul 25, 2024
Drug: Lumateperone 42 mg; Placebo · For: Schizophrenia
Sites: Little Rock, Arkansas; Bellflower, California; Cerritos, California · 43 sites in all
- A Study of Lumateperone Versus Placebo in Participants With Major Depressive DisorderPivotal-lookingNot yet recruiting
Intra-Cellular Therapies, Inc.Industry
NCT07747389 · 585 participants (planned) · Start Nov 11, 2026 · Primary completion Sep 20, 2029
Drug: Lumateperone; Placebo · For: Depressive Disorder, Major
- Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar DepressionPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT02600494 · 554 participants · Start Dec 15, 2015 · Primary completion Jan 28, 2019
Drug: ITI-007 (Lumateperone); Placebo · For: Bipolar Depression
Sites: Little Rock, Arkansas; Rogers, Arkansas; Cerritos, California · 55 sites in all
- Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar DepressionPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT02600507 · 529 participants · Start Mar 7, 2016 · Primary completion Jul 2, 2020
Drug: Lumateperone (ITI-007); Placebo · For: Bipolar Depression
Sites: Rogers, Arkansas; Cerritos, California; Costa Mesa, California · 71 sites in all
- Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT04285515 · 488 participants · Start Feb 27, 2020 · Primary completion Nov 30, 2022
Drug: Lumateperone; Placebos · For: Bipolar Depression; Major Depressive Disorder
Sites: Garden Grove, California; Oceanside, California; Sherman Oaks, California · 42 sites in all
- Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT04985942 · 485 participants · Start Jul 30, 2021 · Primary completion Feb 22, 2024
Drug: Lumateperone; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Glendale, California; Oceanside, California · 54 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness754
- nausea581
- headache523
- somnolence448
- off label use407
- drug ineffective357
- mania315
- anxiety308
- sedation292
- feeling abnormal291
- insomnia279
- fatigue275
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 170 |
| 2021 | 363 |
| 2022 | 980 |
| 2023 | 622 |
| 2024 | 1,997 |
| 2025 | 1,611 |
| 2026 | 1,961 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Caplyta (Lumateperone Tosylate)
2024 spending
$268M
Beneficiaries
27,010
159,224 claims
Per beneficiary
$9,940
$56.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,480,688 |
| 2021 | $47,511,498 |
| 2022 | $108,476,660 |
| 2023 | $194,921,427 |
| 2024 | $268,479,293 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.
McIntyre RS, Stahl SM, Shim SR, et al. · JAMA Psychiatry 2026 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, et al. · Lancet Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.
Wu H, Siafis S, Hamza T, et al. · Schizophr Bull 2022 · Meta-Analysis
- The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features.
McIntyre RS, Durgam S, Huo J, et al. · J Clin Psychiatry 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.
Lin X, Siafis S, Tian J, et al. · CNS Drugs 2025 · Systematic Review, Meta-Analysis
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
Correll CU, Davis RE, Weingart M, et al. · JAMA Psychiatry 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Intra-Cellular
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.